Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE ISSUED JUNE 3, 2021 (FURNISHED PURSUANT TO ITEM 7.01). - Sanara MedTech Inc. | smti_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 3, 2021
|
SANARA MEDTECH INC.
|
|
(Exact
name of registrant as specified in its charter)
|
|
Texas
|
001-39678
|
59-2219994
|
|
(State
or other jurisdiction of
|
(Commission File
Number)
|
(IRS
Employer
|
|
incorporation)
|
|
Identification
No.)
|
|
|
|
|
|
1200 Summit Avenue, Suite 414
Fort Worth, Texas
|
|
76102
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (817) 529-2300
(Former
name or former address, if changed since last report)
Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common
Stock, $0.001 par value
|
|
SMTI
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01
Regulation
FD Disclosure.
On
June 4, 2021, Sanara MedTech Inc. (the “Company”)
issued a press release announcing the closing of an investment in
Pixalere Healthcare Inc. (“Pixalere”). A copy of the
press release is attached as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated by reference herein.
The
information in this Item 7.01, including Exhibit 99.1 attached
hereto, shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth in such
filing.
Item
8.01
Other
Events.
On
June 3, 2021, the Company purchased Class A Preferred Shares (the
“Shares”) of Pixalere that are convertible into 27.3%
of the outstanding equity of Pixalere. Pixalere provides a
cloud-based wound care software tool that empowers nurses,
specialists and administrators to deliver better care for patients.
In connection with the Company’s purchase of the Shares,
Pixalere granted Pixalere Healthcare USA, LLC (“Pixalere
USA”), a subsidiary of the Company, a royalty-free exclusive
license to use the Pixalere software and platform in the United
States. In conjunction with the grant of the license, the Company
issued Pixalere a 27.3% equity ownership interest in Pixalere
USA.
Item
9.01
Financial
Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
Press
Release issued June 4, 2021 (furnished pursuant to Item
7.01).
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date:
|
June 4, 2021
|
|
|
|
|
|
|
|
|
|
|
Sanara MedTech Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Michael D.
McNeil
|
|
|
|
|
Name:
Michael D. McNeil
|
|
|
|
|
Title:
Chief Financial Officer
|